Mind the gap
A campaign by EFPIA, the representative organization for Europe’s research-based biopharmaceutical industry
BMS promotes the protection, and strengthening, of an intellectual property framework in Europe that catalyses transformational new treatments whose discovery, development and delivery to patients demands an enabling policy environment.
The European Commission’s proposed changes to the general pharmaceutical legislation could have a negative effect on Europe’s ability to achieve high standards of care for patients and to draw future investments in biopharmaceutical research and production.
At stake is competitiveness - how well Europe can care for citizens who get sick in the future and how much economic activity it can generate through high-value jobs and investments. In the upcoming review of the general pharmaceutical legislation, let’s stand with innovation. As Europeans, it’s part of who we are.